A Phase 3 interventional study of insulin degludec/liraglutide and insulin aspart in Diabetes and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 60 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-20.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 — 4 open to participants now, 4 under way, 2 of them phase 3. insulin degludec · Diabetes Mellitus, Type 2.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, this one is the 64th largest by enrollment, is one of 3 that started in 2014, is one of 49 in phase 3, and was the 41st registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →4 of the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2 are open now, in 2 countries. Recruiting first, the newest first:
Gan and Lee Pharmaceuticals, USA · Sites in Germany
Ages 18–70
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · Sites in China
Ages 18–70
Yanbing Li
Ages 18–70
Tonghua Dongbao Pharmaceutical Co.,Ltd
Ages 18–75
By country, each count listing its studies:
insulin degludec: first FDA approval 2015 (RYZODEG 70/30), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →
Of the 883 Diabetes Mellitus, Type 2 studies recruiting now, 374 (42%) set no upper age limit and 383 (43%) stop at 75 or younger; 52 take children under 18; 205 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
70 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 3 · Phase 3 50 · Phase 4 8
First in 2006; this study’s year is marked. 3 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 31 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 384 across the 70 interventional studies. Of the 64 that completed or were terminated, 51 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
59 of 70 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S: 25 open now, 29 under way, 11 of them phase 3. Of 603 finished, 174 (29%) have results posted.
Among the 643 studies in Diabetes Mellitus, Type 2 by Novo Nordisk A/S, this one is the 368th largest by enrollment of the 428 interventional ones that give a count, is one of 22 that started in 2014, is one of 187 in phase 3, and was the 374th registered.
Novo Nordisk A/S’s Diabetes Mellitus, Type 2 studies by the year they started, since 1997.
1 of the studies testing insulin degludec in Diabetes Mellitus, Type 2 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07173712Yanbing LiRegimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes | 2027-06-30 |
Add it to your calendar (.ics) → With an account.
Among the 70 studies testing insulin degludec in Diabetes Mellitus, Type 2, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novo Nordisk A/S’s 643 in Diabetes Mellitus, Type 2:
This tab as a report to print or save as PDF → With an account.
This trial is conducted globally. The aim of the trial is to compare sequential addition of insulin aspart versus further dose increase with insulin degludec/liraglutide in subjects with type 2 diabetes mellitus, previously treated with insulin degludec/liraglutide and metformin and in need of further intensification.
This is an extension to trial NN9068-3952, NCT01952145 (DUAL™ V).
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
This study's enrollment of 31 is below the median of 80 across 8,359 interventional studies indexed under Diabetes Mellitus, Type 2.
Browse Diabetes Mellitus, Type 2 studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Diabetes Mellitus, Type 2, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Diabetes Mellitus. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: insulin degludec/liraglutide
Drug: insulin degludec/liraglutide · Drug: insulin aspart
Drug pages: Insulin degludec · Liraglutide
Insulin degludec/liraglutide will be given subcutaneously (s.c., under the skin) once daily in combination with metformin. Dose individually adjusted.
Dose titration of insulin aspart will be based on the respective pre-meal(s) and bedtime SMPG measured daily.
Change From Baseline in HbA1c (Glycosylated Haemoglobin)
Change from baseline in HbA1c after 26 weeks of treatment.
Time frame: Week 0, week 26
Change From Baseline in Body Weight
Change from baseline in body weight after 26 weeks of treatment.
Time frame: Week 0, week 26
Number of Treatment-emergent Confirmed Hypoglycaemic Episodes
Treatment-emergent hypoglycaemic episodes: if the onset of the episode occurred on or after the first day of investigational medicinal product administration, and no later than 7 days after the last day on investigational medicinal product. Confirmed hypoglycaemia: subject unable to treat himself/herself and/or have a recorded plasma glucose \< 3.1 mmol/L (56 mg/dL).
Time frame: Week 0 - 26
The trial was conducted at 19 sites in 8 countries as follows: Argentina: 2 sites; Greece: 2 sites, Hungary: 1 site; Russian Federation: 5 sites; Slovakia: 4 sites, South Africa: 1 site; Spain: 1 site, United States: 3 sites.
| Milestone | IDegLira | IDegLira + IAsp |
|---|---|---|
| Started | 16 | 15 |
| Completed | 14 | 13 |
| Not completed | 2 | 2 |
| Withdrew: Unclassified | 1 | 2 |
| Withdrew: Withdrawal criteria | 1 | 0 |
Change from baseline in HbA1c after 26 weeks of treatment.
| Percentage of glycosylated haemoglobin | IDegLira | IDegLira + IAsp |
|---|---|---|
| Change From Baseline in HbA1c (Glycosylated Haemoglobin) | -0.43 ± 0.94 | -0.14 ± 1.09 |
Change from baseline in body weight after 26 weeks of treatment.
| Kilograms | IDegLira | IDegLira + IAsp |
|---|---|---|
| Change From Baseline in Body Weight | 0.9 ± 2.1 | 1.5 ± 3.2 |
Treatment-emergent hypoglycaemic episodes: if the onset of the episode occurred on or after the first day of investigational medicinal product administration, and no later than 7 days after the last day on investigational medicinal product. Confirmed hypoglycaemia: subject unable to treat himself/herself and/or have a recorded plasma glucose \< 3.1 mmol/L (56 mg/dL).
| Number of episodes | IDegLira | IDegLira + IAsp |
|---|---|---|
| Number of Treatment-emergent Confirmed Hypoglycaemic Episodes | 34 | 4 |
Collected over From first trial-related activity (week 0) after the subject had signed the informed consent until the end of the post-treatment follow-up period (week 27).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IDegLira | — | 1/16 (6.3%) | 11/16 (68.8%) |
| IDegLira + IAsp | — | 2/15 (13.3%) | 3/15 (20%) |
| Event | IDegLira | IDegLira + IAsp |
|---|---|---|
| Chronic myeloid leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/16 | 1/15 |
| Renal failureRenal and urinary disorders | 0/16 | 1/15 |
| Acute coronary syndromeCardiac disorders | 1/16 | 0/15 |
| Coronary revascularisationSurgical and medical procedures | 1/16 | 0/15 |
| Event | IDegLira | IDegLira + IAsp |
|---|---|---|
| Abdominal painGastrointestinal disorders | 0/16 | 1/15 |
| Amylase increasedInvestigations | 0/16 | 1/15 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/16 | 1/15 |
| Back painMusculoskeletal and connective tissue disorders | 1/16 | 1/15 |
| Cardiac murmurInvestigations | 0/16 | 1/15 |
| DiarrhoeaGastrointestinal disorders | 0/16 | 1/15 |
| HyperkalaemiaMetabolism and nutrition disorders | 0/16 | 1/15 |
| Lipase increasedInvestigations | 1/16 | 1/15 |
| Oedema peripheralGeneral disorders | 0/16 | 1/15 |
| Renal cystRenal and urinary disorders | 0/16 | 1/15 |
Baseline characteristics were presented for full analysis set (FAS = 31 subjects).
| Age, Continuous(Years) | IDegLira | IDegLira + IAsp | Total |
|---|---|---|---|
| Mean | 57.3 ± 11.7 | 57.4 ± 11.2 | 57.4 ± 11.3 |
| Gender(Participants) | IDegLira | IDegLira + IAsp | Total |
|---|---|---|---|
| Female | 9 | 8 | 17 |
| Male | 7 | 7 | 14 |
| HbA1c(Percentage of glycosylated haemoglobin) | IDegLira | IDegLira + IAsp | Total |
|---|---|---|---|
| Mean | 7.6 ± 0.9 | 7.7 ± 0.7 | 7.6 ± 0.8 |
The record gives a start of Apr 2014, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.
Results were first posted in Jan 2017, 1 year 9 months after primary completion. A results delay was requested in Nov 2016.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Insulin degludec · Liraglutide